Mazdutide (100 mg Vial) Dosage Protocol
Mazdutide is a dual GLP-1 / glucagon receptor agonist studied for obesity and type-2 diabetes. Phase 2 trials report substantial weight loss with the dual mechanism distinct from GLP-1/GIP agonists.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and weekly dosing
Standard / Gradual Titration (3 mL = 33.33 mg/mL)
| Week | Weekly Dose | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 2.5 mg (2,500 mcg) | 7.5 units (0.075 mL) |
| Weeks 5–8+ | 5 mg (5,000 mcg) | 15 units (0.15 mL) |
Frequency: Inject once weekly subcutaneously. This schedule mirrors clinical trial protocols with gradual titration to improve tolerability. The 3.0 mL dilution provides practical unit measurements for standard maintenance doses.
Reconstitution Steps
- Draw 3 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl until dissolved (do not shake vigorously).
- Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Advanced / High‑Dose Protocol (3 mL = 33.33 mg/mL)
| Week | Weekly Dose | Units (per injection) (mL) | Notes |
|---|---|---|---|
| Weeks 1–4 | 5 mg (5,000 mcg) | 15 units (0.15 mL) | 0.5 vials |
| Weeks 5–8 | 7.5 mg (7,500 mcg) | 22.5 units (0.225 mL) | 0.75 vials |
| Weeks 9–12+ | 10 mg (10,000 mcg) | 30 units (0.3 mL) | 1 vial |
Caution: High‑dose protocols (7.5–10 mg weekly) have been explored in phase 1b research but require careful monitoring and clinical oversight. Doses above 6 mg increase the risk of gastrointestinal side effects. The 2.0 mL reconstitution provides higher concentration to reduce injection volume. For doses requiring >3.0 mL total volume, split into two separate injections at different sites.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Calculated from the schedule above for a 100 mg vial reconstituted with 3 mL (one injection per day, two swabs per injection).
| Item | 8 weeks | 12 weeks | 16 weeks |
|---|---|---|---|
| Peptide vials (100 mg each) | 3 vials (210 mg total) | 4 vials (350 mg total) | 5 vials (490 mg total) |
| Insulin syringes (U-100) | 56 syringes | 84 syringes | 112 syringes |
| Bacteriostatic water (10 mL bottles) | 9 mL → 1 × 10 mL bottle | 12 mL → 2 × 10 mL bottles | 15 mL → 2 × 10 mL bottles |
| Alcohol swabs | 112 swabs → 2 × 100-count boxes | 168 swabs → 2 × 100-count boxes | 224 swabs → 3 × 100-count boxes |
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days, protect from light |
Important Notes
How This Works
Mazdutide is an oxyntomodulin analog activating both GLP-1 and glucagon receptors. GLP-1 activation provides appetite suppression and improved glucose handling; glucagon activation increases energy expenditure. The combination produces weight loss with a mechanism complementary to GLP-1/GIP dual agonists.
Potential Benefits & Side Effects
Potential Benefits
- Phase 2 obesity: ~12–15% weight reduction at 6 mg weekly.
- Improvements in HbA1c in type-2 diabetes trials.
- Reductions in liver fat content reported.
- Once-weekly dosing.
Side Effect Profile
- Nausea, vomiting, diarrhea (typical incretin GI profile).
- Decreased appetite.
- Injection-site reactions.
Lifestyle Factors
- Hydration, protein intake, resistance training — standard incretin protocol.
- Smaller meals, slow titration to manage GI burden.
Injection Technique
- Subcutaneous, abdomen/thigh/upper arm. Rotate weekly.
- Room-temp solution, 90° angle.